Clinical Trial Update: Estrogen Replacement to Reduce Risk of Neurologic Injury After Coronary Artery Bypass Graft Surgery [NA]

View source ↗

Summary

The NHLBI-sponsored clinical trial evaluating estrogen replacement to reduce neurologic injury after coronary artery bypass graft surgery has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease
• Coronary Artery Disease

Drugs mentioned

• Estrogen Replacement Therapy (estrogen replacement therapy)

Snippet

Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | Conditions: Coronary Disease, Cardiovascular Diseases | NA | Status: TERMINATED